The University of Chicago Header Logo

Connection

Arlene Chapman to Hydrochlorothiazide

Back to Details
This is a "connection" page, showing publications Arlene Chapman has written about Hydrochlorothiazide.
Arlene Chapman
Connection Strength
3.986
Hydrochlorothiazide
  1. Genetic Variants Associated With Uncontrolled Blood Pressure on Thiazide Diuretic/ß-Blocker Combination Therapy in the PEAR (Pharmacogenomic Evaluation of Antihypertensive Responses) and INVEST (International Verapamil-SR Trandolapril Study) Trials. J Am Heart Assoc. 2017 Nov 02; 6(11).
    View in: PubMed
    Score: 0.609
  2. Night blood pressure responses to atenolol and hydrochlorothiazide in black and white patients with essential hypertension. Am J Hypertens. 2014 Apr; 27(4):546-54.
    View in: PubMed
    Score: 0.453
  3. Predictors of antihypertensive response to a standard dose of hydrochlorothiazide for essential hypertension. Kidney Int. 2002 Mar; 61(3):1047-55.
    View in: PubMed
    Score: 0.206
  4. Genetic Variants Influencing Plasma Renin Activity in Hypertensive Patients From the PEAR Study (Pharmacogenomic Evaluation of Antihypertensive Responses). Circ Genom Precis Med. 2018 04; 11(4):e001854.
    View in: PubMed
    Score: 0.157
  5. Sphingolipid Metabolic Pathway Impacts Thiazide Diuretics Blood Pressure Response: Insights From Genomics, Metabolomics, and Lipidomics. J Am Heart Assoc. 2017 12 29; 7(1).
    View in: PubMed
    Score: 0.154
  6. Whole Transcriptome Sequencing Analyses Reveal Molecular Markers of Blood Pressure Response to Thiazide Diuretics. Sci Rep. 2017 11 22; 7(1):16068.
    View in: PubMed
    Score: 0.153
  7. Genome-Wide Prioritization and Transcriptomics Reveal Novel Signatures Associated With Thiazide Diuretics Blood Pressure Response. Circ Cardiovasc Genet. 2017 Jan; 10(1).
    View in: PubMed
    Score: 0.144
  8. Genome-Wide and Gene-Based Meta-Analyses Identify Novel Loci Influencing Blood Pressure Response to Hydrochlorothiazide. Hypertension. 2017 01; 69(1):51-59.
    View in: PubMed
    Score: 0.142
  9. A Genetic Response Score for Hydrochlorothiazide Use: Insights From Genomics and Metabolomics Integration. Hypertension. 2016 09; 68(3):621-9.
    View in: PubMed
    Score: 0.139
  10. TET2 and CSMD1 genes affect SBP response to hydrochlorothiazide in never-treated essential hypertensives. J Hypertens. 2015 Jun; 33(6):1301-9.
    View in: PubMed
    Score: 0.129
  11. Predictors for glucose change in hypertensive participants following short-term treatment with atenolol or hydrochlorothiazide. Pharmacotherapy. 2014 Nov; 34(11):1132-40.
    View in: PubMed
    Score: 0.122
  12. Genomic association analysis of common variants influencing antihypertensive response to hydrochlorothiazide. Hypertension. 2013 Aug; 62(2):391-7.
    View in: PubMed
    Score: 0.112
  13. The role of plasma renin activity, age, and race in selecting effective initial drug therapy for hypertension. Am J Hypertens. 2013 Aug; 26(8):957-64.
    View in: PubMed
    Score: 0.111
  14. Effects of genetic variation in H3K79 methylation regulatory genes on clinical blood pressure and blood pressure response to hydrochlorothiazide. J Transl Med. 2012 Mar 22; 10:56.
    View in: PubMed
    Score: 0.103
  15. Blood pressure responses and metabolic effects of hydrochlorothiazide and atenolol. Am J Hypertens. 2012 Mar; 25(3):359-65.
    View in: PubMed
    Score: 0.101
  16. Lack of association between polymorphisms in STK39, a putative thiazide response gene, and blood pressure response to hydrochlorothiazide. Pharmacogenet Genomics. 2010 Aug; 20(8):516-9.
    View in: PubMed
    Score: 0.092
  17. Comparison of office, ambulatory, and home blood pressure antihypertensive response to atenolol and hydrochlorthiazide. J Clin Hypertens (Greenwich). 2010 Jan; 12(1):14-21.
    View in: PubMed
    Score: 0.088
  18. Impact of abdominal obesity on incidence of adverse metabolic effects associated with antihypertensive medications. Hypertension. 2010 Jan; 55(1):61-8.
    View in: PubMed
    Score: 0.088
  19. Lack of correlation between thiazide-induced hyperglycemia and hypokalemia: subgroup analysis of results from the pharmacogenomic evaluation of antihypertensive responses (PEAR) study. Pharmacotherapy. 2009 Oct; 29(10):1157-65.
    View in: PubMed
    Score: 0.087
  20. Genomic association analysis suggests chromosome 12 locus influencing antihypertensive response to thiazide diuretic. Hypertension. 2008 Aug; 52(2):359-65.
    View in: PubMed
    Score: 0.080
  21. WNK1 kinase polymorphism and blood pressure response to a thiazide diuretic. Hypertension. 2005 Oct; 46(4):758-65.
    View in: PubMed
    Score: 0.066
  22. Demographic, environmental, and genetic predictors of metabolic side effects of hydrochlorothiazide treatment in hypertensive subjects. Am J Hypertens. 2005 Aug; 18(8):1077-83.
    View in: PubMed
    Score: 0.065
  23. A multilocus approach to the antihypertensive pharmacogenetics of hydrochlorothiazide. Pharmacogenet Genomics. 2005 May; 15(5):287-93.
    View in: PubMed
    Score: 0.064
  24. Lack of agreement between office and ambulatory blood pressure responses to hydrochlorothiazide. Am J Hypertens. 2005 Mar; 18(3):398-402.
    View in: PubMed
    Score: 0.063
  25. Circulating microRNA Biomarkers of Thiazide Response in Hypertension. J Am Heart Assoc. 2024 Feb 20; 13(4):e032433.
    View in: PubMed
    Score: 0.059
  26. Effects of endothelial nitric oxide synthase, alpha-adducin, and other candidate gene polymorphisms on blood pressure response to hydrochlorothiazide. Am J Hypertens. 2003 Oct; 16(10):834-9.
    View in: PubMed
    Score: 0.057
  27. Interacting effects of gender and genotype on blood pressure response to hydrochlorothiazide. Kidney Int. 2002 Nov; 62(5):1718-23.
    View in: PubMed
    Score: 0.054
  28. Reproducibility of blood pressure response to hydrochlorothiazide. J Clin Hypertens (Greenwich). 2002 Nov-Dec; 4(6):408-12.
    View in: PubMed
    Score: 0.054
  29. Race-Specific Comparisons of Antihypertensive and Metabolic Effects of Hydrochlorothiazide and Chlorthalidone. Am J Med. 2021 07; 134(7):918-925.e2.
    View in: PubMed
    Score: 0.047
  30. Pharmacogenomics of hypertension: a genome-wide, placebo-controlled cross-over study, using four classes of antihypertensive drugs. J Am Heart Assoc. 2015 Jan 26; 4(1):e001521.
    View in: PubMed
    Score: 0.031
  31. PROX1 gene variant is associated with fasting glucose change after antihypertensive treatment. Pharmacotherapy. 2014 Feb; 34(2):123-30.
    View in: PubMed
    Score: 0.029
  32. Hypertension susceptibility loci and blood pressure response to antihypertensives: results from the pharmacogenomic evaluation of antihypertensive responses study. Circ Cardiovasc Genet. 2012 Dec; 5(6):686-91.
    View in: PubMed
    Score: 0.027
  33. G protein receptor kinase 4 polymorphisms: ß-blocker pharmacogenetics and treatment-related outcomes in hypertension. Hypertension. 2012 Oct; 60(4):957-64.
    View in: PubMed
    Score: 0.027
  34. Genomic association analysis identifies multiple loci influencing antihypertensive response to an angiotensin II receptor blocker. Hypertension. 2012 Jun; 59(6):1204-11.
    View in: PubMed
    Score: 0.026
  35. Power to identify a genetic predictor of antihypertensive drug response using different methods to measure blood pressure response. J Transl Med. 2012 Mar 13; 10:47.
    View in: PubMed
    Score: 0.026
  36. Pharmacogenomics of antihypertensive drugs: rationale and design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study. Am Heart J. 2009 Mar; 157(3):442-9.
    View in: PubMed
    Score: 0.021
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.